Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00892
|
|||||
| Drug Name |
Gallopamil
|
|||||
| Synonyms |
(+/-)-Methoxyverapamil hydrochloride; 16662-47-8; 5-((3,4-Dimethoxyphenethyl)(methyl)amino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile; 5-[(3,4-Dimethoxyphenethyl)methylamino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile; Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4,5-trimethoxy-alpha-(1-methylethyl)-; C28H40N2O5; CHEBI:34772; D 600; D600; GSK 796406; Gallopamil [INN:BAN]; Gallopamillum [INN-Latin]; Galopamilo; Galopamilo [INN-Spanish]; Methoxyverapamil; methoxyverapamil
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Asthma [ICD11: CA23] | Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C28H40N2O5
|
|||||
| Canonical SMILES |
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C(=C2)OC)OC)OC
|
|||||
| InChI |
InChI=1S/C28H40N2O5/c1-20(2)28(19-29,22-17-25(33-6)27(35-8)26(18-22)34-7)13-9-14-30(3)15-12-21-10-11-23(31-4)24(16-21)32-5/h10-11,16-18,20H,9,12-15H2,1-8H3
|
|||||
| InChIKey |
XQLWNAFCTODIRK-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 16662-46-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 484.6 | Topological Polar Surface Area | 73.2 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 14 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:34772
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT00896428) Effects of Gallopamil in Severe Asthma | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.